+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
17 Nov 2019

Insignt on Roche’s Up-to-$1.4Billion Promedior Acquisition

Posted By

Roche has agreed to acquire Promedior for up to $1.4 billion.

Roche’s deal will give it full rights to Promedior’s entire portfolio of molecules for serious fibrotic diseases—a pipeline anchored by PRM-151, a recombinant form of human pentraxin-2 (PTX-2) protein that earlier this year generated positive Phase II results in idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF).

Roche agreed to pay $390 million cash upfront, and up to $1 billion in payments tied to achieving development, regulatory, and commercial milestones. The acquisition is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.


Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests